Home World News FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and Older... World News FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and Older with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas By Ogkologos - September 25, 2025 473 0 Facebook Twitter Google+ Pinterest WhatsApp Approval was based on findings from the Study 89, SPRINT and the SPRINKLE trials Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR ESMO Breast Cancer 2024, 15-17 May, Berlin, Germany May 8, 2024 Should People With Cancer Be Tested for Hepatitis B? July 27, 2020 FDA Approves Cabozantinib for Differentiated Thyroid Cancer September 30, 2021 ΚΑΡΚΙΝΟΣ ΠΝΕΥΜΟΝΑ November 22, 2018 Load more HOT NEWS Four Different Doctors Misdiagnosed Woman’s Breast Pain Because “Breast Cancer Doesn’t... On legacy giving: “It allows me to give something more meaningful... Breathing for Stress Reduction News digest – larger waistlines and prostate cancer, GP gut instincts...
